SCHEMBL3457415

SCHEMBL3457415

O=C(O)[C@H]1CCC(CN(C(=O)N2CCOCC2)C2CC2)C[C@@H]1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.36
POLB P06746 2/20 0.36
PKM P14618 1/20 0.36
KMT2A Q03164 4/20 0.35
MEN1 O00255 1/20 0.35
HTT P42858 1/20 0.35
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 4/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPT P10636 1/20 0.34
ADAM10 O14672 1/20 0.33
ERBB2 P04626 1/20 0.33
MMP2 P08253 1/20 0.33
PIK3CD O00329 1/20 0.32
LMNA P02545 3/20 0.32
KDM1A O60341 1/20 0.31
CTSS P25774 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.30
RAB9A P51151 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2176649 0.91 HPGD (0.35) HPGDPOLBPKMKMT2AMEN1
SCHEMBL2175039 0.74 ADAM10 (0.56) MAPTADAM10ERBB2MMP2CTSS
SCHEMBL12323192 0.72 POLB (0.54) HPGDPOLBPKMKMT2AMEN1
SCHEMBL12282345 0.70 PIK3CD (0.59) HPGDPOLBPKMKMT2AMEN1
SCHEMBL19607353 0.69 DPP4 (0.42) HPGDPOLBPKMKMT2AALDH1A1
SCHEMBL16424010 0.68 ALDH1A1 (0.45) HPGDPOLBPKMKMT2AMEN1
SCHEMBL5761060 0.66 ALDH1A1 (0.43) HPGDPOLBKMT2AMEN1ALDH1A1
SCHEMBL18485318 0.66 ALDH1A1 (0.43) HPGDPOLBKMT2AMEN1ALDH1A1
SCHEMBL7389926 0.65 SMN1; SMN2 (0.42) HPGDPOLBKMT2AMEN1ALDH1A1
SCHEMBL3369288 0.64 NSD2 (0.43) KDM4EPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150025056-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION (US) 2015-01-22 US disclosed
US-8853243-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2014-10-07 US disclosed
EP-2264030-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases Incyte Corporation (US) 2010-12-22 EP disclosed
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases LNCYTE CORPORATION (US) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025056-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP2, MMP14 HPGD 50/4885POLB 1479/4885PKM 1701/4885
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases MMP25, MMP9, MMP24 HPGD 33/4885POLB 2157/4885PKM 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.